Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMX-001 in head and neck cancer
NCT04607642Phase 2Withdrawn
- Sponsor
- BioMimetix
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
01
Overview
A Phase 2 trial of manganese butoxyethyl pyridyl porphyrin in oral mucositis (OM), xerostomia, sponsored by BioMimetix. Planned start Jul 2021; status: withdrawn.
02
Drugs
manganese butoxyethyl pyridyl porphyrin
03
Conditions
oral mucositis (OM)xerostomia
Beyond the preview
Go deeper on NCT04607642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607642.